In 2008 the Department of Health in the UK produced a short booklet entitled 'Medicines Management: Everybody's Business. A guide for service users, carers and health and social care practitioners.' This document which was devised by carers and users was heavily scrutinised by psychaitrists and the DH so that it was more acceptable. The genotyping test which was initally promised by the director of NIMHE was eventually rejected from the document. Scores of publications were destroyed some months later.
www.newwaysofworking.org.uk Pharmacy Section.
This leaflet is an improvement on the previous situation, however does still not convey the full picture of all the potential adverse reactions.
Much of the pharmaceutical literature contains information resulting from short term studies i.e. six to eight weeks. However the long term studies about the insidious and long lasting impact on the brain and the physical body together with the psychological impact is in my experience, never shared with patients and carers. Long term studies are not in general undertaken.
The current Mental Health practice of withholding all neuroleptic/anti-psychotic side effects/adverse reaction information, I think is wrong, since patients and carers are prevented from having a truly informed choice about neuroleptic 'medication'.
In my experience challenging prescribers about side effects has resulted with the robotic response that the 'benefits of neuroleptics far out weigh the risks'. This attitude I think is uncaring and does not happen in general medicine where physical effects affecting body organs are taken seriously. Such psychiatric prescribers are in denial to the physical and psychological suffering incurred by service users and indirectly by carers.
The Lancet, 352 (9130) 784. states longer service users take psychotropic drugs the more likely will be the severity of side effects. Reporting of Side Effects to the Medicines and Healthcare products Regulatory Agency
Yellow Cards are available on line at www.mhra.gov.uk, or from pharmacies, GP surgeries or the Yellow Card hotline (0808 100 3352) during business hours.Schizophrenia Association of Great Britain reports adverse events and deaths form the following neuroleptics:
- Clozapine: period 19.12.89 -7.03.01:
2813 Adverse events with 622 cardiovascular disorder
Many other systems were reported
106 Adverse events with 46 cardiovascular disorderMany other systems were reported
- Sertindole: period from 01.07.96 - 24.07.00
247 Adverse events with 15 cardiovascular disorderMany other systems were reported
- Amisulpiride: period between 26.01.98 - 23.03.01
Adverse events with 231 cardiovascular disorder. Many other systems were reported
- Olanzapine: period between 01.10.96 - 28.03.01 391699
Adverse events with 80 cardiovascular disorderMany other systems were reported
- Quetiapine: period between 04.10.97 - 19.03.01302
822 Adverse events with 139 cardiovascular disorderMany other systems were reported
14 Adverse events with 6 cardiovascular disorder
- Zotepine: period between 16.12.98 - 15.01.01
Other systems reported.